Andrew Moreo

Head of Process Development • Andelyn Biosciences

Andrew Moreo, provides daily control as well as strategic guidance for the process development.  He ensures that all activities within the process development and preclinical manufacturing teams.  He ensures that all activities within the process development are within compliance standards.  Mr. Moreo has over 20 years of experience in genetic and molecular research. He has worked for RINCH for the past 13 years focusing on AAV including the development of the current AAV production platform.  Mr. Moreo has a BS in Biology from Purdue University

Also Speaking

Kimberly Goodspeed

Assistant Professor • University of Texas Southwestern Medical Center

Gregory Fiore

Founder and Chief Executive Officer • Exacis Biotherapeutics

Christian Chabannon

Head of Center for Cell Therapy • GoCART Coalition

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.